^
    Back
    Association details:
    Biomarker:PGR positive
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2022
    Title:

    Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial

    Published date:
    05/26/2022
    Excerpt:
    The Short-HER study randomized 1254 patients with HER2+ early breast cancer to receive 9 weeks vs 1 year of adjuvant trastuzumab combined with anthracycline-taxane chemotherapy. 853 patients with HR+ BC (ER and/or PgR >10%) were included…patients who received AI had a significantly better DFS as compared to patients who received TAM or TAM-AI: 7-yr DFS 87.3% vs 81.7%, log-rank P=0.017 (HR 1.46, 95%CI 1.05-2.03).
    Secondary therapy:
    Aromatase inhibitor; Chemotherapy
    DOI:
    10.1200/JCO.2022.40.16_suppl.547
    Trial ID:
    ShortHER
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

    Excerpt:
    ...- Estrogen receptor- and/or progesterone receptor-positive tumor...
    Trial ID:
    SAKK 23/03
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer

    Excerpt:
    ...- Estrogen receptor or progesterone receptor positive...
    Trial ID:
    NCT00053339
    More C2 evidence